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Abstract
Objective
Arthropathy that mimics osteoarthritis (OA) and osteoporosis (OP) is considered a compli-
cation of hereditary hemochromatosis (HH). We have limited data comparing OA and OP
prevalence among HH patients with different hemochromatosis type 1 (HFE) genotypes.
We investigated the prevalence of OA and OP in patients with HH by C282Y homozygosity
and compound heterozygosity (C282Y/H63D) genotype.
Methods
A total of 306 patients with HH completed a questionnaire. Clinical and demographic char-
acteristics and presence of OA, OP and related complications were compared by genotype,
adjusting for age, sex, body mass index (BMI), current smoking and menopausal status.
Results
In total, 266 of the 306 patients (87%) were homozygous for C282Y, and 40 (13%) were
compound heterozygous. The 2 groups did not differ by median age [60 (interquartile range
[IQR] 53 to 68) vs. 61 (55 to 67) years, P=0.8], sex (female: 48.8% vs. 37.5%, P=0.18) or
current smoking habits (12.4% vs. 10%, P=0.3). As compared with compound heterozy-
gous patients, C282Y homozygous patients had higher median serum ferritin concentration
at diagnosis [1090 (IQR 610 to 2210) vs. 603 (362 to 950) µg/L, P<0.001], higher median
transferrin saturation [80% (IQR 66 to 91%) vs. 63% (55 to 72%), P<0.001]) and lower me-
dian BMI [24.8 (22.1 to 26.9) vs. 26.2 (23.5 to 30.3) kg/m2, P<0.003]. The overall preva-
lence of self-reported OA was significantly higher with C282Y homozygosity than
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compound heterozygosity (53.4% vs. 32.5%; adjusted odds ratio [aOR] 2.4 [95% confi-
dence interval 1.2–5.0]), as was self-reported OP (25.6% vs. 7.5%; aOR 3.5 [1.1–12.1]).
Conclusion
Patients with C282Y homozygosity may be at increased risk of musculoskeletal complica-
tions of HH.
Introduction
Hereditary hemochromatosis (HH) is an autosomal recessive disorder characterized by in-
creased absorption of dietary iron and rapid iron release from macrophages, which leads to ab-
normal accumulation of iron in several organs, particularly the liver, joints and bones [1, 2]. In
patients with iron overload, 2 hemochromatosis type 1 (HFE) genotypes have been commonly
described: C282Y homozygosity and C282Y/H63D compound heterozygosity. Among patients
of northern European descent, the most common genotype is C282Y homozygosity, account-
ing for about 80% to 90% of HH cases [2].
The musculoskeletal complications of HH have been mainly described in C282Y homozy-
gous patients. These complications consist of an arthropathy that mimics osteoarthritis (OA)
and osteoporosis (OP) [3, 4]. The prevalence of OA ranges from 20% to 80% in homozygous
patients with HH [4]. In addition, such patients are at increased risk of joint replacement [5].
The reported prevalence of OP in these patients ranges from 25% to 35% and OP seems to be
associated with severity of iron overload [1].
Recently, there has been renewed interest in the role of HFE compound heterozygosity
(C282Y/H63D) in the development of HH. Patients with the C282Y/H63D genotype show
iron overload but to a lesser extent than in homozygotes, particularly in the absence of co-
morbid factors [6, 7]. Little is known about the risk of hemochromatosis-related musculoskele-
tal complications with HFE compound heterozygosity.
We aimed to compare the prevalence of HH-related OA and OP in patients with C282Y ho-
mozygosity and those with compound heterozygosity (C282Y/H63D).
Patients and Methods
Patients with HH
Patients who were members of the Association Hémochromatose France (AHF) completed a
self-administered questionnaire that was previously described [8]. Patients were informed of the
purpose of the study and gave their informed consent to be in the study. This study was con-
ducted in accordance with the recommendations of the Helsinki Declaration. The Institutional
Review Board (IRB00006477- Comité d’évaluation de l’éthique des projets de recherche biomé-
dicale du GHU Nord-Hôpital Bichat, Paris) reviewed and approved the study (no. 10–074).
We collected the following data: demographic characteristics (age, sex, weight, height, cur-
rent smoking habit, menopausal status); details of HH history (HFE genotype, ferritin concen-
tration and transferrin saturation at diagnosis, symptoms before diagnosis); general clinical
features (asthenia, diabetes mellitus, heart disease); joint and spine involvement (patients were
asked if they had received a diagnosis of OA by a physician; if they had ever complained of low
back pain or sciatica; if they had knee-, hip-, or ankle-replacement prosthesis); and bone in-
volvement (patients were asked if they had received a diagnosis of OP by a physician; if they
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had a history of fractures). To confirm the validity of the genotype reported by patients, we
reviewed the medical records of a sample of 20 patients followed in our department who had
reported having homozygosity (n = 10) and duplex heterozygosity (n = 10). The rate of
concordance was 95% (19 of 20). One patient who declared homozygosity was actually
compound heterozygous.
Statistical analysis
Continuous variables were tested for normality and homoscedasticity. Some continuous vari-
ables were non-normally distributed (skewed). Therefore, variables were described with the
median and interquartile range (IQR). Differences between groups were assessed by the Mann-
Whitney test. The association between categorical variables was tested by chi-square test.
Crude odds ratios (ORs) were calculated by an univariate logistic regression model, with the
patient genotype (C282Y/C282Y vs. C282Y/H63D) as the independent variable and the out-
come of interest as the dependent variable. Adjusted ORs (aORs) were calculated by a multiple
logistic regression model, with the patient genotype and clinically relevant confounders as in-
dependent variables and the outcome of interest as the dependent variable. The design of the
study precluded the assessment of iron overload by liver biopsy, so we used ferritin concentra-
tion as a surrogate marker, with severity of iron overload defined by serum ferritin concentra-
tion1000 μg/L at diagnosis. This cut-off was previously found clinically appropriate [9].
All statistical analyses involved use of Stata 13.1 (StataCorp, College Station, TX). A 2-tailed
p<0.05 was considered statistically significant.
Results
Demographic and clinical characteristics of patients
In total, 306 patients with HH completed the questionnaire. The sample characteristics are
shown in Table 1. The median age of patients was 60 years (IRQ 53 to 68 years); 47.4% were fe-
males (80% menopausal). Overall, 266 patients (87%) were C282Y/C282Y homozygous and 40
(13%) were C282Y/H63D compound heterozygous. Median serum ferritin concentration at di-
agnosis was significantly higher with C282Y homozygosity than compound heterozygosity
[1090 (IQR 610 to 2210) vs. 603 (362 to 950) μg/L, P<0.001], as was median transferrin satura-
tion [80% (IQR 66 to 91%) vs. 63% (55 to 72%), P<0.001]. The proportion of patients with se-
vere iron overload (> 1000 μg/L) was greater with C282Y homozygosity than C282Y/H63D
compound heterozygosity (52.4% vs. 20%, P< 0.001).
Table 1. Characteristics of patients with hereditary hemochromatosis by genotype.
C282Y/C282Y n = 266 C282Y/H63D n = 40 P value
Age, years 60 (53–68) 61 (55–67) 0.50
Women, % 48.8 37.5 0.18
Body mass index, kg/m2 24.8 (22.1–26.9) 26.2 (23.5–30.3) 0.003
Menopausal women, % 77.6 80 0.80
Current smoker, % 13.2 7.5 0.30
Serum ferritin concentration at diagnosis, μg/L 1090 (610–2210) 603 (362–950) < 0.001
Transferrin saturation, % 80 (66–91) 63 (55–72) < 0.001
Data are median (interquartile range) or percentage. NS: not signiﬁcant
doi:10.1371/journal.pone.0122817.t001
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Self-reported symptoms at the time of the survey
The prevalence of self-reported joint pain at the time of the survey was significantly higher
with C282Y homozygosity than C282Y/H63D compound heterozygosity (88.4% vs. 77.5%,
aOR = 2.8 [95% confidence interval (95% CI) 1.2–6.9]; Table 2). The prevalence of self-reported
asthenia, diabetes and cardiac disease did not differ between the genotypes.
OA, joint replacement and spine involvement
The prevalence of OA was higher with C282Y homozygosity than C282Y/H63D compound
heterozygosity: 53.4% vs. 32.5% (aOR = 2.4 [95% CI 1.2–5.0]; Table 3). This difference was no
longer significant on adjustment for ferritin concentration (aOR = 1.66 [0.79–3.5]). The preva-
lence of hip replacement was higher for homozygotes than heterozygotes–11.7% vs. 7.5%
(aOR = 1.5 [0.41–5.1])—but this difference did not reach statistical significance. The preva-
lence of self-reported back pain and sciatica did not differ between the groups: 71.8% vs. 70%
and 47.4% vs. 45%, respectively.
OP and fractures
In total, 155 patients (50.7%) reported than they had undergone dual-energy X-ray absorpti-
ometry (DEXA). All the patients who self-reported OP also reported having undergone DEXA.
The prevalence of OP was greater for C282Y homozygous than compound heterozygous pa-
tients (25.6% vs. 7.5%; aOR = 3.5 [95% CI 1.1–12.1]); Table 4). The effect of genotype on the
prevalence of OP was no longer statistically significant on adjustment for ferritin concentration
(aOR = 2.6 [0.74–9.3]). The prevalence of hip, wrist and vertebral fractures did not differ be-
tween the groups: 2.6% vs. 2.5%, 13.2% vs. 7.5% and 7.9% vs. 2.5%, respectively.
Table 2. Prevalence of self-reported symptoms at the time of the survey by genotype.
C282Y/C282Y n = 266 C282Y/H63D n = 40 Crude OR (95% CI) aOR*(95% CI) P value
Joint pain, % 88.4 77.5 2.2 (0.96–5.1) 2.8 (1.2–6.9) 0.02
Asthenia, % 79.3 82.1 0.82 (0.34–1.9) 0.8 (0.33–1.9) 0.56
Diabetes, % 9.7 10 0.98 (0.32–2.9) 1.2 (0.37–3.9) 0.87
Cardiac disease, % 15.4 17.5 0.86 (0.36–2.1) 0.98 (0.39–2.5) 0.83
OR, odds ratio; aOR, adjusted OR; 95% CI, 95% conﬁdence interval.
*Adjusted for age, sex, body mass index and current smoking habits.
doi:10.1371/journal.pone.0122817.t002
Table 3. Prevalence of osteoarthritis, joint replacement, back pain and sciatica by genotype.
C282Y/C282Y n = 266 C282Y/H63D n = 40 Crude OR(95% CI) aOR*(95% CI) P value
Osteoarthritis, % 53.4 32.5 2.4 (1.2–4.8) 2.4 (1.2–5) 0.02
Knee replacement, % 5.6 5.0 1.1 (0.25–5.1) 1.5 (0.3–7.1) 0.64
Hip replacement, % 11.7 7.5 1.6 (0.47–5.6) 1.5 (0.41–5.1) 0.08
Ankle replacement, % 0.75 2.5 0.3 (0.03–3.3) 0.32 (0.025–4) 0.52
Back pain, % 71.8 70 1.1 (0.53–2.3) 1.2 (0.55–2.6) 0.31
Sciatica, % 47.4 45 1.1 (0.56–2.1) 1.3 (0.65–2.6) 0.59
* Adjusted for age, sex and body mass index.
doi:10.1371/journal.pone.0122817.t003
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Discussion
We investigated the prevalence of OA and OP, HH-related musculoskeletal complications, by
C282Y homozygosity and compound heterozygosity (C282Y/H63D) genotype and found the
prevalence of both self-reported OA and OP higher for patients with C282Y homozygosity
than compound heterozygosity.
Our study population consisted of 306 patients, the C282Y/C282Y genotype being 6.7 times
more frequent than the C282Y/H63D genotype, which agrees with previous studies of patients
with HH-related musculoskeletal complications [10, 11]. As expected, as compared with pa-
tients with compound heterozygosity, those with the homozygous C282Y/C282Y genotype
showed significantly higher ferritin concentration and transferrin saturation values, and about
half of the homozygous patients showed severe iron overload. BMI was greater for compound
heterozygous than homozygous patients, as was found recently [6]. Indeed, co-morbid factors
such as alcohol abuse and overweight are more prevalent in C282Y/H63D than C282Y/C282Y
patients [6].
In HH, abnormally increased iron absorption leads to iron loading of parenchymal cells in
the liver, pancreas, heart and joints, with subsequent damage to structure and impaired func-
tion [2]. The reasons for the high frequency of the musculoskeletal system involvement in HH
are unknown [2].
In this study, the 2 genotype groups did not differ in prevalence of self-reported asthenia,
cardiac disease or diabetes, which is similar to findings by Waalen et al. [12], showing that pa-
tients with different genotypes of HFE self-reported similar rates of symptoms commonly asso-
ciated with iron overload.
Several studies have well documented the association of HH and an arthropathy that may
seriously affect quality of life [1, 8, 13]. This arthropathy can be severe, as highlighted by the
high prevalence of hip, knee and ankle joint replacement in these patients [5, 8, 10].
In our study, the prevalence of self-reported OA was greater in patients with C282Y homo-
zygosity than C282Y/H63D compound heterozygosity, after adjustment for confounding vari-
ables. The prevalence of hip replacement surgery was greater but not significantly for C282Y
homozygous than compound heterozygous patients, as was found recently [14]. This increased
prevalence of OA in C282Y homozygotes might be related to the more severe iron overload in
these patients. Indeed, this difference was no longer significant after adjustment for ferritin
concentration. Although the role of iron overload in the genesis of HH-related OA is still not
fully understood, iron overload can lead to iron accumulation in the synovium and cartilage of
HH patients, as seen on histology [1], and to increased ferritin concentration in synovial fluid
[15]. Some of this iron can be in the form of non-transferrin–bound iron and might have dele-
terious effects [16] on synovial tissue, promoting inflammation with neutrophil infiltration
[17] and tissue damage, as was demonstrated in the liver [18]. Iron deposits were found in sy-
novial tissue from patients with inflammatory arthritis [1], which suggests a link between iron
Table 4. Prevalence of osteoporosis and associated fractures by genotype
C282Y/C282Y n = 266 C282Y/H63D n = 40 Crude OR(95% CI) aOR*(95% CI) P value
Osteoporosis, % 25.6 7.5 4.3 (1.3–14.2) 3.5 (1.1–12.1) 0.04
Hip fracture, % 2.6 2.5 1.1(0.13–8.8) 0.66 (0.07–6.3) 0.64
Wrist fracture, % 13.2 7.5 1.9 (0.55–6.4) 2.3 (0.65–8.2) 0.45
Vertebral fracture, % 7.9 2.5 3.3 (0.44–25.6) 3.3 (0.42–26) 0.15
* Adjusted for age, sex, body mass index, menopausal status and smoking habits
doi:10.1371/journal.pone.0122817.t004
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content and inflammation. More recently, the serum level of vascular adhesion molecule 1 was
found associated with radiographic measures of HH arthropathy, which suggests its involve-
ment in HH joint damage [19].
Patients with HH have shown disc degeneration and calcifications in the intervertebral discs
due to calcium pyrophosphate crystal deposits [20]. In a retrospective study [21], one third of
patients with HH showed spine arthropathy on radiography. The literature contains no data
on the prevalence of low back pain in patients with a clinical phenotype of HH. Both our geno-
type groups showed similar self-reported prevalence of low back pain and sciatica, which sug-
gests that the lumbar spine involvement in HH is independent of the genotype.
We found an increased prevalence of OP, along with increased prevalence, although not sig-
nificant, of vertebral fractures in homozygote patients. Again, this observation could be related
to the increased iron overload observed in C282Y homozygotes. Indeed, the impact of the ge-
notype on the prevalence of OP was no longer significant when we adjusted for ferritin concen-
tration. Several reports have shown that HH patients, particularly males, are at increased risk
of OP, which might be related to iron overload [1, 22].
The pathophysiology of OP in HH is not entirely clear. Animal and in vitro data support
that iron excess can affect bone formation and remodeling [1]. Iron-overloaded mice show in-
creased level of reactive oxygen species, serum tumor necrosis factor α and interleukin 6, asso-
ciated with severity of iron overload [23]. HFE-/- mice show impaired bone microarchitecture
and increased osteoclast number [24]. In vitro, iron disrupts the formation of hydroxyapatite
crystals and inhibits the proliferation and differentiation of osteoblasts [1].
There are several limitations and caveats to this study. Patients were asked to remember
symptoms or fractures attributed to hemochromatosis, which might suggest recall bias. As for
all surveys, this study may lack robust internal validity. Because of the relatively low number of
patients with compound heterozygosity, the number of rare events such as fractures or joint re-
placement surgery was low in this group, which might explain the non-significant findings for
joint replacement and fracture. Finally, we could not differentiate symptomatic and
asymptomatic fractures.
Conclusions
To conclude, this is the first study to compare the effect of genotype on HH-related musculo-
skeletal symptoms. C282Y homozygosity may confer increased risk of OA and OP as compared
with C282Y/H63D compound heterozygosity.
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